Aventis Pharma S.a.

Other

Fr&eacute;d&eacute;ric Revah

Jacques Mallet

Michel Perricaudet

Emmanuelle Vigne

Fran&ccedil;oise Finiels

Minerva Gimenez-Ribotta

Alain Privat

Axel Kahn

Marc Abitbol

Paul Roustan

Georg Haase

Philippe Kennel

Philippe Horellou

The invention concerns a novel method for treating motor neuron diseases and particularly amyotrophic lateral sclerosis. It consists more particularly in the systemic administration of expression systems of neurotrophic factors.

Method for treating amyotrophic lateral sclerosis

Recombinant adenoviruses comprising a heterologous DNA sequence coding for basic blast growth factors (bFGF), preparation and uses thereof for the treatment and/or prevention of neurodegenerative diseases.

Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF)

The present invention relates to methods and compositions for delivering a nucleic acid to motor neurons administering the nucleic acid to muscle tissue. The invention relates to methods for treating pathologies of the nervous system, such as trauma and neurodegenerative diseases.

Adenoviral-vector-mediated gene transfer into medullary motor neurons

The present invention relates to methods and compositions for delivering nucleic acids to motor neurons by administering the nucleic acids to muscle tissue. The invention relates to methods for treating pathologies of the nervous system, such as trauma and neurodegenerative diseases.

Muscle reinnervation and motor axon sprouting by administering DNA sequences encoding NT-3 and CNTF

Recombinant adenoviruses comprising a heterologous DNA sequence coding for glial-derived neurotrophic growth factor (GDNF) are provided. The recombinant adenoviruses are useful in a method of expressing GDNF in a cell, wherein the cell is present in a mammal suffering from Parkinson's disease, comprising infecting said cell with a replication-defective recombinant adenovirus comprising a DNA sequence encoding GDNF operably linked to a promoter by administering the adenovirus into cells of the central nervous system. The recombinant adenoviruses of the invention are also useful in a method of treating Parkinson's disease comprising administering into cells of the central nervous system of a mammal suffering therefrom a replication defective recombinant adenovirus comprising ITRs, an encapsidation sequence and a DNA sequence encoding GDNF operably linked to a promoter, wherein the adenovirus E1 gene is non-functional and GDNF is expressed at a level that provides a therapeutic effect.

Recombinant adenoviruses coding for glial-derived neurotrophic factor (GDNF)

Growing community of inventors

Paris, France

Frédéric Revah

Growing community of inventors

Paris, France

Fr&eacute;d&eacute;ric Revah

Frédéric Revah